AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$PAHC

What Phibro Animal Health (PAHC) Said on Its Q1 Earnings Call

Phibro Animal Health (PAHC) reported Q1 adjusted EBITDA fell $1M due to higher SG&A expenses, despite increased gross profit. Mineral Nutrition and Performance Products sales rose 17% and 16%, respectively, with EBITDA gains. Companywide operating income declined $1.6M. Phibro maintained fiscal 2027 guidance, with net sales expected between $1.55B and $1.6B. Brazilian regulatory discussions continue, with no sales included in the forecast. Free cash flow was $22M over the past year.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 10:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Phibro Animal Health (PAHC) Said on Its Q1 Earnings Call — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$PAHCBearishMed
01

Why it matters

The earnings miss and modest guidance suggest near‑term pressure on PAHC, though strategic moves like inventory cuts and plant closure may improve margins later.

02

Market read

First disclosure of FY2027 guidance for PAHC; traders should reassess valuation and exposure.

03

What to watch

Potential upside from Brazilian virginiamycin approval and inventory reductions could offset guidance concerns.

Relevance 7/10Novelty 7/10Timing: post-earnings release today

Background

Phibro Animal Health (NASDAQ:PAHC) released its Q1 earnings, highlighting segment performance, cash flow, and FY2027 outlook.

Company-level read

Ticker impact

$PAHCBearishHigh confidence
Context

Q1 earnings call disclosed adjusted EBITDA miss and FY2027 guidance ranges for net sales, EBITDA and EPS.

Expected impact

likely downside as market prices in slower growth outlook

Evidence & confidence

The company reported a $1M EBITDA shortfall and set FY2027 guidance that signals limited upside, prompting traders to consider short positions or reduce exposure.

Market effects

Sector

Animal health sector may see broader scrutiny of margin pressures.

Regional

North American animal health producers could face similar margin challenges.

Global

Limited to niche livestock feed additive market.

Counterpoint

What could challenge this read

Guidance still reflects growth; investors may view the modest miss as a buying opportunity if the stock is oversold.

Key entities

  • Executive
    David Bendheim

    CEO who presented the earnings and guidance.

Read at source← All news

StoryPhibro Animal Health posts Q1 earnings beat and maintains FY2027 guidance

Also covered by

1 outlet

Related articles

$PAHCMedAI 8/10

Phibro Animal (PAHC) Q1 2027 Earnings Call Transcript

Phibro Animal Health (PAHC) reported Q1 2027 sales growth of 6% to $386.8M and adjusted EBITDA growth of 4% to $64.3M. Performance Products and Mineral Nutrition segments drove growth, while Animal Health saw a 3% increase. The company maintained its full-year guidance and expects protein demand to grow, despite near-term pressure on producer profitability.

finance.yahoo.com
$PAHCHighAI 8/10

Phibro Animal Health Corp (PAHC) (Q1 2027) Earnings Call Highlights: Solid Start to Fiscal

Phibro Animal Health (PAHC) reported Q1 2027 sales of $386.8M (+6%) and adjusted EBITDA of $64.3M (+4%). CEO Donnie Bantine expects Brazil Virginiamycin approval but no sales assumed in 2027. Zoetis portfolio drove MFA growth, while livestock margins are squeezed. USDA's border reopening impacts cattle imports. Net income rose 11% to $29.5M. Guidance remains unchanged, with net sales expected between $1.55B-$1.6B.

finance.yahoo.com
$PAHCHighAI 8/10

Phibro Animal Health (NASDAQ:PAHC) exceeds Q3 CY2026 expectations

Phibro Animal Health (PAHC) reported Q3 CY2026 revenue of $386.8M, beating estimates by 3% and growing 6.3% year-on-year. Adjusted EPS met expectations at $0.79. Adjusted EBITDA rose 3.9% to $64.3M. The company reconfirmed its full-year revenue guidance of $1.58B and adjusted EPS guidance of $3.50, with EBITDA guidance of $263M, above analyst estimates.

finance.yahoo.com
$PAHCMed

Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance

PHIBRO ANIMAL HEALTH CORP (PAHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ For Immediate Release ​ Phibro Animal Health Corporation Reports First Quarter Results, Maintains Financial Guidance ​ TEANECK, N.J., November 4, 2026 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced

SEC EDGAR 8-K
$PAHCMedAI 8/10

Phibro Animal Health (PAHC) Sets 2027 Guidance, Is The Stock Still A Bargain?

Phibro Animal Health (PAHC) issued 2027 guidance, projecting net sales of $1.55b-$1.60b and net income of $122m-$132m. The company reported 2026 sales of $1.518b and net income of $99.72m. Analysts' price targets range from $38 to $58, with a consensus of $45.60, suggesting a 16.1% undervaluation. The stock has seen a 90-day return of 17.95% and a 3-year return above 200%.

yahoo.com